JP2006516286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516286A5 JP2006516286A5 JP2006501034A JP2006501034A JP2006516286A5 JP 2006516286 A5 JP2006516286 A5 JP 2006516286A5 JP 2006501034 A JP2006501034 A JP 2006501034A JP 2006501034 A JP2006501034 A JP 2006501034A JP 2006516286 A5 JP2006516286 A5 JP 2006516286A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- nhcor
- represented
- sarm
- conhr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims 87
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 87
- 150000001875 compounds Chemical class 0.000 claims 56
- 125000000217 alkyl group Chemical group 0.000 claims 51
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 48
- 229910052736 halogen Inorganic materials 0.000 claims 44
- 150000002367 halogens Chemical group 0.000 claims 44
- 239000000126 substance Substances 0.000 claims 44
- 229910052794 bromium Inorganic materials 0.000 claims 36
- 229910052801 chlorine Inorganic materials 0.000 claims 36
- 229910052731 fluorine Inorganic materials 0.000 claims 36
- 229910052740 iodine Inorganic materials 0.000 claims 36
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 28
- 101100149678 Caenorhabditis elegans snr-3 gene Proteins 0.000 claims 24
- 125000004122 cyclic group Chemical group 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 24
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 20
- 125000003342 alkenyl group Chemical group 0.000 claims 20
- 125000004982 dihaloalkyl group Chemical group 0.000 claims 20
- 125000001188 haloalkyl group Chemical group 0.000 claims 20
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 20
- 210000003169 central nervous system Anatomy 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 229910052717 sulfur Inorganic materials 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 13
- 150000001204 N-oxides Chemical class 0.000 claims 8
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 8
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 8
- 210000000988 bone and bone Anatomy 0.000 claims 8
- 239000013078 crystal Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 239000007788 liquid Substances 0.000 claims 8
- 239000002207 metabolite Substances 0.000 claims 8
- 210000003205 muscle Anatomy 0.000 claims 8
- 239000008188 pellet Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000007787 solid Substances 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 201000004384 Alopecia Diseases 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 201000009273 Endometriosis Diseases 0.000 claims 6
- 206010058359 Hypogonadism Diseases 0.000 claims 6
- 208000029725 Metabolic bone disease Diseases 0.000 claims 6
- 206010049088 Osteopenia Diseases 0.000 claims 6
- 208000001132 Osteoporosis Diseases 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 206010036049 Polycystic ovaries Diseases 0.000 claims 6
- 201000001880 Sexual dysfunction Diseases 0.000 claims 6
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 6
- 231100000360 alopecia Toxicity 0.000 claims 6
- 208000007502 anemia Diseases 0.000 claims 6
- 230000001149 cognitive effect Effects 0.000 claims 6
- 230000003247 decreasing effect Effects 0.000 claims 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 6
- 208000001076 sarcopenia Diseases 0.000 claims 6
- 231100000872 sexual dysfunction Toxicity 0.000 claims 6
- 206010046766 uterine cancer Diseases 0.000 claims 6
- 208000010428 Muscle Weakness Diseases 0.000 claims 5
- 206010028372 Muscular weakness Diseases 0.000 claims 5
- 102000001307 androgen receptors Human genes 0.000 claims 5
- 108010080146 androgen receptors Proteins 0.000 claims 5
- 206010002261 Androgen deficiency Diseases 0.000 claims 4
- 229940124011 Androgen receptor agonist Drugs 0.000 claims 4
- 229940123407 Androgen receptor antagonist Drugs 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 230000001270 agonistic effect Effects 0.000 claims 4
- 230000001195 anabolic effect Effects 0.000 claims 4
- 239000003936 androgen receptor antagonist Substances 0.000 claims 4
- 230000001548 androgenic effect Effects 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- 239000006071 cream Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- -1 elixir Substances 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 4
- 239000012530 fluid Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 230000003637 steroidlike Effects 0.000 claims 4
- 239000000829 suppository Substances 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 239000003826 tablet Substances 0.000 claims 4
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000036651 mood Effects 0.000 claims 2
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 0 Cc1cc(*)c(C*)c2c1CCCC2 Chemical compound Cc1cc(*)c(C*)c2c1CCCC2 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44130803P | 2003-01-22 | 2003-01-22 | |
| PCT/US2004/001359 WO2004064747A2 (en) | 2003-01-22 | 2004-01-20 | Treating androgen deficiency in female (adif)-associated conditions with sarms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006516286A JP2006516286A (ja) | 2006-06-29 |
| JP2006516286A5 true JP2006516286A5 (cg-RX-API-DMAC7.html) | 2007-01-25 |
Family
ID=32771915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006501034A Pending JP2006516286A (ja) | 2003-01-22 | 2004-01-20 | Ｓａｒｍによる女性のアンドロゲン減少に関連する病気の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050032750A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1594490A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006516286A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1771031A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004206909A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2514024A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200503729A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004064747A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
| US20040260108A1 (en) * | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| US8445534B2 (en) | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
| CA2501874A1 (en) * | 2002-10-16 | 2004-04-29 | Gtx, Inc. | Treating androgen decline in aging male (adam)-associated conditions with sarms |
| US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
| US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| FI20030958A0 (fi) * | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
| MXPA06002462A (es) * | 2003-10-14 | 2006-06-20 | Gtx Inc | Tratamiento de desordenes relacionados con huesos con moduladores del receptor de angrogeno selectivo. |
| US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
| EP1945224B1 (en) | 2005-10-19 | 2012-05-02 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| KR100785038B1 (ko) * | 2006-04-17 | 2007-12-12 | 삼성전자주식회사 | 비정질 ＺｎＯ계 ＴＦＴ |
| DK2038252T3 (en) * | 2006-07-12 | 2016-12-19 | Univ Tennessee Res Found | SUBSTITUTED AND ACYLANILIDER methods of use thereof |
| US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| EP3056483A1 (en) * | 2006-08-24 | 2016-08-17 | University of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| EP2523556A4 (en) | 2010-01-11 | 2013-08-28 | Gtx Inc | METHOD FOR TREATING MIBROMED DYNAMIC FUNCTION |
| FR2982261B1 (fr) | 2011-11-04 | 2014-06-13 | Galderma Res & Dev | Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| HUE052574T2 (hu) * | 2012-07-13 | 2021-05-28 | Oncternal Therapeutics Inc | Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| AU2015336929B2 (en) | 2014-10-22 | 2021-03-18 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| EP3364978A4 (en) | 2015-10-22 | 2019-06-05 | Havah Therapeutics Pty Ltd | METHOD FOR REDUCING MAMMOGRAPHIC BREAST DENSITY AND / OR BREAST CANCER RISK |
| CN106405064B (zh) * | 2016-08-30 | 2018-10-26 | 嘉兴行健生物科技有限公司 | 一种40岁以上女性骨转换率的评估方法 |
| CN119970752A (zh) | 2019-06-03 | 2025-05-13 | 哈瓦赫治疗有限公司 | 用于递送雄激素剂和芳香酶抑制剂的药物制剂 |
| US11701332B2 (en) | 2020-11-18 | 2023-07-18 | Bryce Nicholas Day | Methods and compositions for treating female sexual interest and arousal disorder |
| US20230172897A1 (en) * | 2021-12-02 | 2023-06-08 | Veru, Inc. | Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents |
| WO2025102293A1 (zh) * | 2023-11-16 | 2025-05-22 | 北京脑科学与类脑研究所 | 神经活性雄激素受体调节剂及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8617653D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
| US5498626A (en) * | 1992-04-10 | 1996-03-12 | Pfizer Inc. | Acylaminoindole derivatives as 5-ht1 agonists |
| US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| ATE344233T1 (de) * | 2000-08-24 | 2006-11-15 | Univ Tennessee Res Corp | Selektive modulatoren des andro genrezeptors und methoden zu deren verwendung |
| KR20040104463A (ko) * | 2002-02-28 | 2004-12-10 | 유니버시티 오브 테네시 리서치 파운데이션 | 비가역적 선택적 안드로겐 수용체 모듈레이터 및 이를사용하는 방법 |
| CA2477737C (en) * | 2002-02-28 | 2012-08-07 | The University Of Tennessee Research Corporation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
| US7022870B2 (en) * | 2002-06-17 | 2006-04-04 | University Of Tennessee Research Foundation | N-bridged selective androgen receptor modulators and methods of use thereof |
| JP2006506369A (ja) * | 2002-10-15 | 2006-02-23 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション | メチレン架橋選択的アンドロゲン受容体調節剤及びその使用方法 |
-
2004
- 2004-01-20 CA CA002514024A patent/CA2514024A1/en not_active Abandoned
- 2004-01-20 CN CNA2004800077667A patent/CN1771031A/zh active Pending
- 2004-01-20 EP EP04703606A patent/EP1594490A4/en not_active Withdrawn
- 2004-01-20 AU AU2004206909A patent/AU2004206909A1/en not_active Abandoned
- 2004-01-20 WO PCT/US2004/001359 patent/WO2004064747A2/en not_active Ceased
- 2004-01-20 US US10/759,538 patent/US20050032750A1/en not_active Abandoned
- 2004-01-20 JP JP2006501034A patent/JP2006516286A/ja active Pending
- 2004-01-27 TW TW093101758A patent/TW200503729A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006516286A5 (cg-RX-API-DMAC7.html) | ||
| JP2006511486A5 (cg-RX-API-DMAC7.html) | ||
| JP2009506119A5 (cg-RX-API-DMAC7.html) | ||
| AU2008239601B2 (en) | Selective androgen receptor modulators for treating diabetes | |
| JP2006505564A5 (cg-RX-API-DMAC7.html) | ||
| JP2006518328A5 (cg-RX-API-DMAC7.html) | ||
| US7772433B2 (en) | SARMS and method of use thereof | |
| CA2538095C (en) | Selective androgen receptor modulators and methods of use thereof | |
| AU2003287076B2 (en) | Heterocyclic selective androgen receptor modulators and methods of use thereof | |
| US20110237664A1 (en) | Selective androgen receptor modulators for treating diabetes | |
| RU2015104780A (ru) | Способ лечения андроген-рецептора(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов(sarm) | |
| US20130034562A1 (en) | Selective androgen receptor modulators for treating diabetes | |
| AU2004206909A2 (en) | Treating androgen deficiency in female (ADIF)-associated conditions with sarms | |
| JP2006514098A5 (cg-RX-API-DMAC7.html) | ||
| JP2005526741A5 (cg-RX-API-DMAC7.html) | ||
| CA2477737A1 (en) | Multi-substituted selective androgen receptor modulators and methods of use thereof | |
| EP1562594A2 (en) | Methylene-bridged selective androgen receptor modulators and methods of use thereof | |
| KR20090030345A (ko) | 선택적인 안드로겐 수용체 모듈레이터, 그 유사체와 유도체, 및 그의 용도 | |
| AU2003287075A1 (en) | Treating obesity with selective androgen receptor modulators | |
| US9889110B2 (en) | Selective androgen receptor modulator for treating hormone-related conditions | |
| US20190055192A1 (en) | Selective androgen receptor modulator and methods of use thereof | |
| CA2501874A1 (en) | Treating androgen decline in aging male (adam)-associated conditions with sarms | |
| US10662148B2 (en) | Selective androgen receptor modulator and methods of use thereof | |
| WO2015061724A1 (en) | Selective androgen receptor modulator and chemotherapeutic agent for treating muscle wasting in cancer patients |